| 1/2 | US=5 / Biol/Mol Kessler T, Bayer M, Schwoppe C, Liersch R, Mesters RM, Berdel WE. Compounds in clinical phase III and beyond. In: Liersch R, Berdel WE, Kessler T. Angiogenesis inhibition. New York: Springer, 2010. p. 137-63. (Recent results in cancer research) ISBN 978-3-540-78280-3. ESTUDOS CLINICOS DE FASE III; ANTICORPO ANTI-VEGF; BEVACIZUMABE; AFLIBERCEPT; SORAFENIBE; SUNITINIBE; AXITINIBE; CEDIRANIBE; VANDETANIBE; VATALANIBE; ENDOSTATINA; TALIDOMIDA |
| 2/2 | US=67 / Biol/Mol Saini S, Hurwitz H. VEGF inhibition for cancer therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 573-84. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. INIBICAO DO VEGF; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; TERAPIA DO CANCER; ANTI-ANGIOGENESE; INIBICAO DA QUINASE DE TIROSINA; BEVACIZUMABE; SORAFENIBE; BAY 43-9006; MALATO DE SUNITINIBE; SU11248; VATALANIBE |